S-ClassAbout S-Class
A
AZNAI Stock Diagnostic Report
AstraZeneca Q2 Non-GAAP EPS tops expectations by $1.36; reconfirms full-year outlook
AstraZeneca's second-quarter non-GAAP earnings per share (EPS) exceeded expectations and reaffirmed its full-year outlook.
View Source Article ↗AI CATALYST SCORE85 / 100Score computed by Sentinel V12
REFERENCE PRICE$169.26Reference entry price at analysis time
01
MARKET SNAPSHOT
Key Indicators at a Glance
02
FUNDAMENTALS
Financial & Fundamental Analysis
Q2 Non‑GAAP EPS exceeded estimates by $1.36, underscoring solid earnings power, and the reaffirmation of annual guidance maintained earnings credibility.
03
TECHNICAL VIEW
Technical Position & Response Criteria
With the RSI at 50.5, there is no clear directional trend; therefore, a response is required after confirming additional momentum.
04
CATALYST & STRATEGY
Catalyst Analysis & Forward Strategy
Earnings surprise and reaffirmation of annual performance outlook.
05
PROOF OF WORK
Analysis Point vs. Subsequent Price Action
INITIAL · At Analysis (2026-07-27)
FINAL · Current/Verified
Renders the actual stored OHLC data directly in your browser.